Clinical Trial

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

Recruiting
View on ClinicalTrials.gov →
Summary
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-04-02; most recent amendment 2026-07-19.
Status change: Not Yet Recruiting → Recruiting 2025-12-01
Trial Details
NCT Number NCT06910306
Lead Sponsor Alpha Tau Medical LTD.
Conditions Recurrent Glioblastoma, Recurrent Gliomas
Enrollment 10 participants
Start Date 2025-10-01
Primary Completion 2026-11-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-21